Pharmaceutical
Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Pharmaceutical · page 3
- Clinical Research
How to Read a Cannabis Research Paper
Why Reading Research Matters The volume of cannabis research has never been higher, but not all studies are created equal.
- Pharmaceutical
Europe’s First Ever ‘Whole Plant’ Cannabis Medicine Could be Available by 2026 in Major Step Forward for Non-Opioid Pain Treatment
German pharmaceutical company Vertanical believes it is on course to deliver the first ‘whole-plant’, cannabis medicine with international approval.
- Pharmaceutical
Standard Seed AI’s Platform Could Rewrite the Future of Cannabis Drug Discovery
At its core, Standard Seed AI’s technology has the power to scientifically validate the entourage effect, streamline drug discovery, and drastically reduce the time and cost of bringing cannabis-based medicines to market.
- Pharmaceutical
Oxford Cannabinoid Technologies Collapses, Dealing Latest Blow to Embattled Cannabis Biotech Sector
Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.
- Pharmaceutical
Slovenia Breaks Cannabis Mould, Latvia to Follow Suit, Bavaria Turns Green, Record Portuguese Exports…And More
THE central European nation of Slovenia is developing proposals which could establish a continental benchmark for medical cannabis.
- Opinion
The Future of Pharmaceuticals: How Cannabinoids Are Redefining the Industry
In recent years, the pharmaceutical landscape has witnessed a seismic shift as cannabinoids transition from niche alternatives to mainstream medical solutions.
- Pharmaceutical
UK Start-up Targets Clinical Proof for Cannabis in Autism Spectrum Disorder
Kingdom Therapeutics, a UK-Irish biotech company, has passed a ‘major milestone’ in its ambitious journey towards launching clinical trials into cannabis and Autism Spectrum Disorder (ASD)
- Pharmaceutical
Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare
Advancing Pharmaceutical Innovation: Brains Bioceutical’s CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals’ CBD-Based Epilepsy Drug and 2024 $1.4 Billion Revenue Projection Brains Bioceutical Corp.
- Pharmaceutical
Ex-GW Pharma Bosses Lead Development of New CBD-Based Epilepsy Drug
As reported by Cannabis Health Avata Biosciences is developing solid dose cannabinoid medicines for epilepsy and other neurological disorders, with a number of former GW Pharmaceutical bosses on board.
- CBD Market
Landmark Study Into CBD & Psychosis To Help Bring Cannabis Into ‘Mainstream’ Research
A NEW landmark study into the effects of cannabidiol (CBD) on psychosis is scheduled to be launched ‘later this year’.
- Pharmaceutical
Canadian wholesale cannabis prices are off more than 40% in 2022
CANADIAN CANNABIS PRICES Canadian wholesale cannabis prices are off more than 40% in 2022 Canadian cannabis wholesale prices tumbled more than 40% last year as companies continued to work through stubborn supply gluts and struggling cultivators chose to sell off their unsold cannabis instead of destroying it, reports MJ Biz Daily.
- Pharmaceutical
Has GW Pharmaceuticals – Now Jazz Pharmaceuticals – Knee-Capped The CBD Industry?
WITH the fast-growing CBD sector tied up in a regulatory quagmire hundreds of transatlantic industry players face an uncertain future.
